| Literature DB >> 29301630 |
Kishore M Gadde1, Corby K Martin2, Hans-Rudolf Berthoud2, Steven B Heymsfield2.
Abstract
Obesity continues to be among the top health concerns across the globe. Despite our failure to contain the high prevalence of obesity, we now have a better understanding of its pathophysiology, and how excess adiposity leads to type 2 diabetes, hypertension, and cardiovascular disease. Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss. Fortunately, 5 drug therapies-orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion-are available for long-term weight management. Additionally, several medical devices are available for short-term and long-term use. Bariatric surgery yields substantial and sustained weight loss with resolution of type 2 diabetes, although due to the high cost and a small risk of serious complications, it is generally recommended for patients with severe obesity. Benefit-to-risk balance should guide treatment decisions.Entities:
Keywords: adipose tissue; antiobesity drugs; bariatric surgery; obesity; overweight; weight loss
Mesh:
Substances:
Year: 2018 PMID: 29301630 PMCID: PMC7958889 DOI: 10.1016/j.jacc.2017.11.011
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094